Biogen Inc.
(NASDAQ : BIIB)

( )
BIIB PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.55%73.740.9%$598.99m
CELGCelgene Corporation
-0.84%129.191.1%$425.21m
AMGNAmgen Inc.
-0.63%169.001.1%$397.19m
BIIBBiogen Inc.
-1.42%282.641.2%$346.45m
REGNRegeneron Pharmaceuticals, Inc.
-0.31%477.152.7%$319.17m
VRTXVertex Pharmaceuticals Incorporated
-1.43%153.251.9%$227.49m
ALXNAlexion Pharmaceuticals, Inc.
-1.83%135.671.9%$211.59m
ILMNIllumina, Inc.
-0.59%193.623.5%$208.34m
KITEKite Pharma, Inc.
1.63%138.1716.1%$135.10m
INCYIncyte Corporation
-0.17%123.652.6%$130.04m
CLVSClovis Oncology, Inc.
-0.68%71.6118.0%$125.25m
TSROTESARO, Inc.
-0.18%120.4014.7%$124.85m
AAgilent Technologies, Inc.
-0.30%62.771.5%$122.45m
BMRNBioMarin Pharmaceutical Inc.
-0.07%81.404.4%$105.16m
SRPTSarepta Therapeutics, Inc.
-2.38%36.0719.8%$88.80m

Company Profile

Biogen, Inc. is a global biotechnology company, which focuses on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. Its products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, and FAMPYRA for multiple sclerosis, ALPROLIX for hemophilia B and ELOCTATE for hemophilia A. The company also collaborates on the development and commercialization of RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is approved for the treatment of chronic lymphocytic leukemia. Biogen was founded by Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.